CA2655094C - Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression - Google Patents

Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression Download PDF

Info

Publication number
CA2655094C
CA2655094C CA2655094A CA2655094A CA2655094C CA 2655094 C CA2655094 C CA 2655094C CA 2655094 A CA2655094 A CA 2655094A CA 2655094 A CA2655094 A CA 2655094A CA 2655094 C CA2655094 C CA 2655094C
Authority
CA
Canada
Prior art keywords
cannabigerol
intra
isolated
depression
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2655094A
Other languages
English (en)
French (fr)
Other versions
CA2655094A1 (en
Inventor
Richard Musty
Richard Deyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of CA2655094A1 publication Critical patent/CA2655094A1/en
Application granted granted Critical
Publication of CA2655094C publication Critical patent/CA2655094C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2655094A 2006-06-15 2007-06-14 Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression Active CA2655094C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81381406P 2006-06-15 2006-06-15
US60/813,814 2006-06-15
PCT/GB2007/002216 WO2007144628A1 (en) 2006-06-15 2007-06-14 Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression

Publications (2)

Publication Number Publication Date
CA2655094A1 CA2655094A1 (en) 2007-12-21
CA2655094C true CA2655094C (en) 2014-09-30

Family

ID=38353631

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2655094A Active CA2655094C (en) 2006-06-15 2007-06-14 Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression

Country Status (5)

Country Link
US (2) US8481085B2 (enExample)
EP (1) EP2037901B1 (enExample)
JP (1) JP5286255B2 (enExample)
CA (1) CA2655094C (enExample)
WO (1) WO2007144628A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644349B1 (en) * 2003-06-24 2014-04-09 GW Pharma Limited Pharmaceutical compositions comprising cabbinochreme type compounds
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US20100293021A1 (en) * 2009-01-23 2010-11-18 Intranet Productivity Solutions, Ltd. Method and system for task tracking and allocation
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
US10045540B2 (en) 2014-04-01 2018-08-14 Fayetteville State University Pest control composition
CA2952934A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2018000094A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3052146A1 (en) 2017-02-01 2018-08-09 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
US10272360B2 (en) 2017-08-05 2019-04-30 Priya Naturals, Inc. Phytochemical extraction system and methods to extract phytochemicals from plants including plants of the family Cannabaceae sensu stricto
AU2018378943A1 (en) * 2017-12-08 2020-07-02 Biotech Institute LLC High cannabigerol cannabis plants, methods of producing and methods of using them
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
ES2973731T3 (es) 2018-04-09 2024-06-24 Portland Tech Holdings Llc Extracto de cáñamo para el tratamiento del dolor en animales
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
BR112021008520A2 (pt) * 2018-10-31 2021-08-03 Baymedica, Inc. análogos de canabinoide e métodos para sua preparação
EP3934641A4 (en) 2019-03-07 2022-12-21 Ilera Therapeutics LLC FORMULATIONS FOR THE TREATMENT OF SYMPTOMS ACCOMPLISHED WITH AUTISM
JP2022550569A (ja) 2019-10-03 2022-12-02 スタートン セラピューティクス，インコーポレイティド ドロナビノールの経皮送達
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CA3150879A1 (en) * 2019-10-08 2021-04-15 Bessor Pharma, Llc Process for the production of cannabinoids and cannabinoid acids
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
JP7670700B2 (ja) 2019-10-11 2025-04-30 パイク セラピューティクス インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CN114555068A (zh) 2019-10-14 2022-05-27 长矛治疗股份有限公司1219014 B.C.有限公司 大麻二酚的透皮给药
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
WO2021102568A1 (en) * 2019-11-26 2021-06-03 Canopy Growth Corporation Cannabinoid derivatives
US12084407B2 (en) 2019-11-26 2024-09-10 Canopy Growth Corporation Cannabigerol derivatives and use thereof as cannabinoid receptor modulators
JP2023505513A (ja) * 2019-12-09 2023-02-09 キャノピー グロウス コーポレイション カンナビノイド誘導体
US11767306B2 (en) 2020-01-17 2023-09-26 Cannacraft, Inc Methods for converting CBD to tetrahydrocannabinols
US20210290564A1 (en) * 2020-03-17 2021-09-23 Tauriga Sciences Inc. Medicated cannabinoid compositions, methods of manufacturing, and methods of treatment
US11786838B2 (en) * 2020-03-23 2023-10-17 Cannacraft, Inc. Methods for removing pesticides from Cannabis products
WO2022026613A2 (en) 2020-07-28 2022-02-03 Impello Biosciences, Inc. Methods and compositions for altering secondary metabolites in plants
EP4271367A4 (en) 2020-12-31 2025-01-01 Cookies Creative Consulting & Promotions, Inc. Compositions comprising cannabis and mushroom extracts, and uses thereof
US11465957B1 (en) 2021-04-08 2022-10-11 MYKU Biosciences LLC Methods and systems for crystallizing and isolating individual cannabinoids
US11345650B1 (en) 2021-04-08 2022-05-31 MYKU Biosciences LLC Methods and systems for crystallizing and isolating individual cannabinoids
CN115504862B (zh) * 2021-06-07 2024-07-05 南通新世元生物科技有限公司 一种大麻萜酚的制备方法
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2023250274A1 (en) 2022-06-22 2023-12-28 Ilera Therapeutics Llc Enhanced capture and dissolution matrix for cannabinoids and methods of making the same
WO2024015780A1 (en) 2022-07-11 2024-01-18 Ilera Therapeutics Llc Zlt-007 and methods of treating diabetic neuropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002246500A1 (en) * 2000-10-27 2002-07-30 Emlin Biosciences Thermal vaporizing device for drug delivery
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
MXPA04011808A (es) * 2002-05-31 2005-09-12 Univ Mississippi Liberacion transmucosica de canabinoides.
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
EP1644349B1 (en) * 2003-06-24 2014-04-09 GW Pharma Limited Pharmaceutical compositions comprising cabbinochreme type compounds

Also Published As

Publication number Publication date
US8481085B2 (en) 2013-07-09
WO2007144628A1 (en) 2007-12-21
US20080031977A1 (en) 2008-02-07
EP2037901A1 (en) 2009-03-25
EP2037901B1 (en) 2014-01-08
US20140039043A1 (en) 2014-02-06
JP5286255B2 (ja) 2013-09-11
CA2655094A1 (en) 2007-12-21
JP2009539961A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
CA2655094C (en) Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression
CA3158059A1 (en) Tryptamine compositions for enhancing neurite outgrowth
US20100292345A1 (en) Therapeutic uses of cannabigerol
CA2653835A1 (en) New use for cannabinoid
WO2013045891A1 (en) A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd)
US20200163931A1 (en) Oral composition of extracted cannabinoids and methods of use thereof
US20230285303A1 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
KR20230121776A (ko) 아마니타 무스카리아 화합물
Zhang et al. Procyanidin protects against 6-hydroxydopamine-induced dopaminergic neuron damage via the regulation of the PI3K/Akt signalling pathway
US12357585B2 (en) Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
Wen et al. A review of nardosinone for pharmacological activities
US8470874B2 (en) Pharmaceutical compositions comprising cannabichromene type compounds
KR101535959B1 (ko) 기관지 수축 질환의 관리 방법
Williams et al. Cannabinoids‐human physiology and agronomic principles for production
NL2022615B1 (en) Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
Das et al. Agarwood as a neuroprotective agent: a comprehensive review of existing evidence and potential avenues for future research
HK1084670B (en) Pharmaceutical compositions comprising cabbinochreme type compounds
US20220296522A1 (en) Bryoid compositions, methods of making and use thereof
TW201309289A (zh) 控制支氣管收縮病狀之方法

Legal Events

Date Code Title Description
EEER Examination request